

Human sCD44var (v5) ELISA Kit



Instruction Manual

PromoKine

Contents

1. Intended Use	3
2. Summary	3
3. Principles of the Test	6
4. Reagents Provided	7
5. Storage Instructions – ELISA Kit	7
6. Specimen Collection and Storage Instructions	8
7. Materials Required But Not Provided	8
8. Precautions for Use	9
9. Preparation of Reagents	10
10. Test Protocol	14
11. Calculation of Results	18
12. Limitations	21
13. Performance Characteristics	21
14. Bibliography	26
15. Reagent Preparation Summary	29
16. Test Protocol Summary	30
17. Ordering Information	31

1. Intended Use

The human sCD44var (v5) ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sCD44var (v5). **The human sCD44var (v5) ELISA is for research use only. Not for diagnostic or therapeutic procedures.**

2. Summary

CD44 (Pgp-1; Ly-24; ECMR III; F10-44-2; H-CAM; HUTCH-I; In(Lu)-related p80; Hermes antigen; hyaluronan receptor) is a polymorphic glycoprotein which participates in a wide variety of cell-cell or cell-matrix interactions including lymphocyte homing, establishment of B and T cell immune responses, tumor metastasis formation and inflammation.

Three isoform categories of the CD44 molecule have been identified:


- a predominant 80-90 kDa category, the so-called standard form named CD44std,
- an intermediate size category of 110-160 kDa and
- a category which includes very large isoforms of 250 kDa covalently modified by the addition of chondroitin sulfate (15).

This CD44-family of transmembrane receptor molecules is derived from a single gene located on chromosome 11. Alternative splicing of the mRNA gives rise to the different isoforms, containing inserts of varying sizes in the extracellular domain of the molecule (exons v2-v10). All CD44 isoforms are variably glycosylated. In contrast to standard CD44 (CD44std) which is almost ubiquitously expressed (18), the variety of CD44 isoforms (CD44var) have a much more restricted distribution, e.g., on keratinocytes (exons v3-v10), epithelial cells (exons v(-v10), activated lymphocytes and macrophages (exon v6) (1,6,10,17).

A splice variant of CD44 (exons v4-v7) confers metastatic behavior in a rat carcinoma model (3); aberrant expression of splice variants has been detected on a variety of human tumor cell lines (7) as well as primary and metastatic human tumors, including lymphomas, carcinomas (colon, thyroid, mamma, bladder), and gliomas (5,6,7,10).

Detection of abnormal regulation of CD44 splicing thus could be helpful in cancer diagnosis and disease evaluation(13).

The sCD44var(v5) ELISA detects all circulating CD44 isoforms comprising the sCD44var(v5) sequences.



Determination of sCD44var(v5) will provide more detailed insight into different pathological modifications during cancer and other diseases.

- **Brain tumors:** CD44 is strongly expressed in high-grade gliomas and weakly expressed in meningiomas, medulloblastomas and normal brain (11).
- **Colorectal carcinomas:** In human colorectal neoplasia CD44 variant proteins are found on all invasive carcinomas and during carcinoma metastasis. Variants are already expressed at a relatively early stage of colorectal carcinogenesis and tumor progression (5).
- **Gastric cancer:** Tumors from patients suffering from stomach adenocarcinomas express CD44 variants. Adenocarcinomas of the intestinal type are strongly positive for exon v5 and v6, whereas diffuse type adenocarcinomas predominantly express exon v5 (4).
- **Lung, breast cancer:** In malignant tissues there is gross overproduction of alternatively-spliced large molecular variants in all samples, whereas in the control samples only the standard

product was routinely detected with occasional minimal quantities of one or two small variants (13).

- **Lymphoma:** In gastrointestinal lymphoma overexpression of CD44 has been correlated with poor survival and more disseminated disease (4,9). Overexpression of CD44 is also found in several aggressive, but not low-grade, non-Hodgkin's lymphomas (10) as well as in Hodgkin's and nodal diffuse lymphomas (2).
- **Tonsil, skin cancer:** Variant CD44 isoform expression can be demonstrated in the plasma membrane of squamous cells of skin and tonsil epithelial and is greatly diminished in malignant squamous epithelial tumors (14,16).
- **HIV:** CD44 is almost completely depleted from the surface of HIV-infected cells (12).
- **Inflammatory joint diseases:** CD44 expression was decreased in synovial fluid neutrophils from most patients (8).

3. Principles of the Test

An anti-human sCD44var (v5) coating antibody is adsorbed onto microwells.

Human sCD44var (v5) present in the sample or standard binds to antibodies adsorbed to the microwells. A HRP-conjugated anti-human sCD44var (v5) antibody is added and binds to human sCD44var (v5) captured by the first antibody.

Following incubation unbound HRP-conjugated anti-human sCD44var (v5) is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

A coloured product is formed in proportion to the amount of human sCD44var (v5) present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 6 human sCD44var (v5) standard dilutions and human sCD44var (v5) concentration determined.

Figure 1




Figure 2




Figure 3





Figure 4



4. Reagents Provided

Reagents for human sCD44var (v5) ELISA Kit (96 tests)

- 1 aluminium pouch with a **Microwell Plate** coated with monoclonal antibody to human sCD44var (v5)
- 2 vials **HRP-Conjugate** anti-human sCD44var (v5) monoclonal antibody
- 2 vials human sCD44var (v5) **Standard** lyophilized, 20 ng/ml upon reconstitution
- 1 bottle (50 ml) **Sample Diluent**
- 1 vial (5 ml) **Assay Buffer Concentrate** 20x (PBS with 1% Tween 20 and 10% BSA)
- 1 bottle (50 ml) **Wash Buffer Concentrate** 20x (PBS with 1% Tween 20)
- 1 vial (15 ml) **Substrate Solution** (tetramethyl-benzidine)
- 1 vial (15 ml) **Stop Solution** (1M Phosphoric acid)
- 1 vial (0.4 ml) **Blue-Dye**
- 1 vial (0.4 ml) **Green-Dye**
- 2 **Adhesive Films**

5. Storage Instructions – ELISA Kit

Store kit reagents between 2°C and 8°C. Immediately after use remaining reagents should be returned to cold storage (2°C to 8°C). Expiry of the kit and reagents is stated on labels.

Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

6. Specimen Collection and Storage Instructions

Cell culture supernatant, serum, plasma (EDTA, citrate, heparin), amniotic fluid and urine were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum or plasma from the clot or cells as soon as possible after clotting and separation.

Pay attention to a possible **“Hook Effect”** due to high sample concentrations (see chapter 11).

Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.

Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human sCD44var (v5). If samples are to be run within 24 hours, they may be stored at 2°C to 8°C (for sample stability refer to 13.5.).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

7. Materials Required But Not Provided

- 5 ml and 10 ml graduated pipettes
- 5 µl to 1000 µl adjustable single channel micropipettes with disposable tips
- 50 µl to 300 µl adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

8. Precautions for Use

- All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.

- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

9. Preparation of Reagents

Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure. If crystals have formed in the **Buffer Concentrates**, warm them gently until they have completely dissolved.

9.1. Wash Buffer (1x)

Pour entire contents (50 ml) of the **Wash Buffer Concentrate** (20x) into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water. Mix gently to avoid foaming.

Transfer to a clean wash bottle and store at 2°C to 25°C. Please note that Wash Buffer (1x) is stable for 30 days.

Wash Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Wash Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

9.2. Assay Buffer (1x)

Pour the entire contents (5 ml) of the **Assay Buffer Concentrate** (20x) into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.

Store at 2°C to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Assay Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

9.3. HRP-Conjugate

Please note that the HRP-Conjugate should be used within 30 minutes after dilution.

Dilute the **HRP-Conjugate** 1:20 just prior to use by adding 190 µl Assay Buffer (1x) to the tube containing the HRP-Conjugate concentrate. Mix the contents of the tube well. Make a further 1:100 dilution with Assay Buffer (1x) in a clean plastic tube.

The second dilution (1:100) of the HRP-Conjugate may be prepared as needed according to the following table:

Number of Strips	Prediluted (1:20) HRP-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

9.4. Human sCD44var (v5) Standard

Reconstitute **human sCD44var (v5) standard** by addition of distilled water.

Reconstitution volume is stated on the label of the standard vial. Swirl or mix gently to insure complete and homogeneous solubilisation (concentration of reconstituted standard = 20 ng/ml).

Allow the reconstituted standard to sit for a minimum of 10 minutes. Mix well prior to making dilutions.

After usage remaining standard cannot be stored and has to be discarded.

Standard dilutions can be prepared directly on the microwell plate (see 10.d) or alternatively in tubes (see 9.4.1.).

9.4.1. External Standard Dilution

Label 6 tubes, one for each standard point.

S1, S2, S3, S4, S5, S6

Then prepare 1:2 serial dilutions for the standard curve as follows:

Pipette 225 µl of Sample Diluent into each tube.


Pipette 225 µl of reconstituted standard (concentration = 20 ng/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 10 ng/ml).

Pipette 225 µl of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer.

Repeat serial dilutions 4 more times thus creating the points of the standard curve (see Figure 5).

Sample Diluent serves as blank.

Figure 5



9.5. Addition of Colour-giving Reagents: Blue-Dye, Green-Dye

In order to help our customers to avoid any mistakes in pipetting the PromoKine ELISAs, PromoCell offers a tool that helps to monitor the addition of even very small volumes of a solution to the reaction well by giving distinctive colours to each step of the ELISA procedure.

This procedure is optional, does not in any way interfere with the test results, and is designed to help the customer with the performance of the test, but can also be omitted, just following the instruction booklet.

Alternatively, the dye solutions from the stocks provided (**Blue-Dye**, **Green-Dye**) can be added to the reagents according to the following guidelines:

- Diluent:** Before standard and sample dilution add the **Blue-Dye** at a dilution of 1:250 (see table below) to the appropriate diluent (1x) according to the test protocol. After addition of **Blue-Dye**, proceed according to the instruction booklet.

5 ml Sample Diluent	20 μ l <i>Blue-Dye</i>
12 ml Sample Diluent	48 μ l <i>Blue-Dye</i>
50 ml Sample Diluent	200 μ l <i>Blue-Dye</i>

2. **HRP-Conjugate:** Before dilution of the concentrated HRP-Conjugate add the *Green-Dye* at a dilution of 1:100 (see table below) to the Assay Buffer (1x) used for the final conjugate dilution. Proceed after addition of *Green-Dye* according to the instruction booklet: Preparation of HRP-Conjugate.

3 ml Assay Buffer (1x)	30 μ l <i>Green-Dye</i>
6 ml Assay Buffer (1x)	60 μ l <i>Green-Dye</i>

10. Test Protocol

- a. Predilute your samples before starting with the test procedure. Dilute serum, plasma and urine samples 1:6 with Sample Diluent according to the following scheme:


20 μ l sample + 100 μ l Sample Diluent

- b. Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2-8°C sealed tightly.
- c. Wash the microwell strips twice with approximately 400 μ l **Wash Buffer** per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about **10 – 15 seconds** before aspiration. Take care not to scratch the surface of the microwells.

After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. **Do not allow wells to dry.**

- d. **Standard dilution on the microwell plate** (Alternatively the standard dilution can be prepared in tubes - see 9.4.1.): Add 100 μ l of Sample Diluent in duplicate to all **standard wells**. Pipette 100 μ l of prepared **standard** (see Preparation of Standard 9.4., concentration = 20 ng/ml) in duplicate into well A1 and A2 (see Table.1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 10 ng/ml), and transfer 100 μ l to wells B1 and B2, respectively (see Figure 6). Take care not to scratch the inner surface of the microwells. Continue this procedure 4 times, creating two rows of human sCD44var (v5) standard dilutions ranging from 10.00 to 0.31 ng/ml. Discard 100 μ l of the contents from the last microwells (F1, F2) used.

Figure 6



In case of an **external standard dilution** (see 9.4.1.), pipette 100 μ l of these standard dilutions (S1 - S6) in the standard wells according to Table 1.

Table 1

Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

	1	2	3	4
A	Standard 1 (10.00 ng/ml)	Standard 1 (10.00 ng/ml)	Sample 2	Sample 2
B	Standard 2 (5.00 ng/ml)	Standard 2 (5.00 ng/ml)	Sample 3	Sample 3
C	Standard 3 (2.50 ng/ml)	Standard 3 (2.50 ng/ml)	Sample 4	Sample 4
D	Standard 4 (1.25 ng/ml)	Standard 4 (1.25 ng/ml)	Sample 5	Sample 5
E	Standard 5 (0.63 ng/ml)	Standard 5 (0.63 ng/ml)	Sample 6	Sample 6
F	Standard 6 (0.31 ng/ml)	Standard 6 (0.31 ng/ml)	Sample 7	Sample 7
G	Blank	Blank	Sample 8	Sample 8
H	Sample 1	Sample 1	Sample 9	Sample 9

- e. Add 100 µl of **Sample Diluent** in duplicate to the **blank wells**.
- f. Add 80 µl of **Sample Diluent** to the **sample wells**.
- g. Add 20 µl of each prediluted **sample** in duplicate to the **sample wells**.
- h. Prepare **HRP-Conjugate** (see Preparation of HRP-Conjugate 9.3.).
- i. Add 50 µl of **HRP-Conjugate** to all wells.
- j. Cover with an adhesive film and incubate at room temperature (18°C to 25°C) for 3 hours, if available on a microplate shaker set at 400 rpm.

- k. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point c. of the test protocol. Proceed immediately to the next step.

- l. Pipette 100 µl of **TMB Substrate Solution** to all wells.

- m. Incubate the microwell strips at room temperature (18°C to 25°C) for about 10 minutes. Avoid direct exposure to intense light.

The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable.

Determination of the ideal time period for colour development has to be done individually for each assay.

It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.9–0.95.

- n. Stop the enzyme reaction by quickly pipetting 100 µl of **Stop Solution** into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2–8°C in the dark.
- o. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

Note: In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

11. Calculation of Results

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human sCD44var (v5) concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human sCD44var (v5) for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human sCD44var (v5) concentration.
- If instructions in this protocol have been followed samples have been diluted 1:30 (1:6 external predilution, 1:5 dilution on the plate: 20 μ l sample + 80 μ l Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 30).**
- Calculation of samples with a concentration exceeding standard 1 may result in incorrect, low human sCD44var (v5) levels (Hook Effect). Such samples require further external predilution according to expected human sCD44var (v5) values with Sample Diluent in order to precisely quantitate the actual human sCD44var (v5) level.**
- It is suggested that each testing facility establishes a control sample of known human sCD44var (v5) concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 7. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 7

Representative standard curve for human sCD44var (v5) ELISA. Human sCD44var (v5) was diluted in serial 2-fold steps in Sample Diluent. Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.




Table 2

Typical data using the human sCD44var (v5) ELISA

Measuring wavelength: 450 nm

Reference wavelength: 620 nm

Standard	Human sCD44var (v5) Concentration (ng/ml)	O.D. at 450 nm	Mean O.D. at 450 nm	C.V. (%)
1	10.00	1.997	2.034	2.5
	10.00	2.071		
2	5.00	0.997	0.989	1.0
	5.00	0.981		
3	2.50	0.451	0.453	0.6
	2.50	0.454		
4	1.25	0.210	0.204	3.7
	1.25	0.198		
5	0.63	0.094	0.095	1.8
	0.63	0.097		
6	0.31	0.044	0.044	0.0
	0.31	0.044		
Blank	0	0.022	0.024	8.3
	0	0.026		

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

12. Limitations

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.
- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

13. Performance Characteristics

13.1. Sensitivity

The limit of detection of human sCD44var (v5) defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 0.14 ng/ml (mean of 6 independent assays).

13.2. Reproducibility

13.2.1. Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human sCD44var (v5). 2 standard curves were run on each plate. Data below show the mean human sCD44var (v5) concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 3.6%.

Table 3

The mean human sCD44var (v5) concentration and the coefficient of variation for each sample

Sample	Experiment	Mean Human sCD44var (v5) Concentration (ng/ml)	Coefficient of Variation (%)
1	1	66	3.0
	2	65	3.2
	3	65	4.3
2	1	32	2.6
	2	34	4.4
	3	33	1.3
3	1	194	2.5
	2	208	2.0
	3	244	1.6
4	1	146	4.5
	2	166	1.6
	3	160	2.5
5	1	119	3.6
	2	136	1.2
	3	126	2.6
6	1	48	6.4
	2	55	6.2
	3	51	3.9

7	1	52	9.9
	2	59	4.1
	3	56	2.8
8	1	42	7.3
	2	59	2.3
	3	55	3.0

13.2.2. Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human sCD44var (v5). 2 standard curves were run on each plate. Data below show the mean human sCD44var (v5) concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 5.8%.

Table 4

The mean human sCD44var (v5) concentration and the coefficient of variation of each sample

Sample	Mean Human sCD44var (v5) Concentration (ng/ml)	Coefficient of Variation (%)
1	66	0.6
2	33	1.7
3	215	9.8
4	157	5.3
5	127	5.3
6	51	5.1
7	56	4.8
8	52	13.8

13.3. Spike Recovery

The spike recovery was evaluated by spiking 4 levels of human sCD44var (v5) into different pooled normal serum samples. Recoveries were determined in 2 independent experiments with 4 replicates each. The amount of endogenous human sCD44var (v5) in unspiked serum was subtracted from the spike values. The recovery ranged from 84% to 100% with an overall mean recovery of 92%.

13.4. Dilution Parallelism

4 serum samples with different levels of human sCD44var (v5) were analysed at serial 2 fold dilutions with 4 replicates each. The recovery ranged from 98% to 129% with an overall recovery of 110% (see Table 5).

Table 5

Sample	Dilution	Expected Human sCD44var (v5) Concentration (ng/ml)	Observed Human sCD44var (v5) Concentration (ng/ml)	Recovery of Expected Human sCD44var (v5) Concentration (%)
1	1:30	--	67	--
	1:60	34	41	121
	1:120	20	21	104
	1:240	10	10	98
2	1:30	--	200	--
	1:60	100	123	123
	1:120	62	72	117
	1:240	36	36	101
3	1:30	--	170	--
	1:60	85	106	125
	1:120	53	60	114
	1:240	30	32	107
4	1:30	--	140	--
	1:60	70	90	129
	1:120	45	53	117
	1:240	26	26	101

13.5. Sample Stability

13.5.1. Freeze-Thaw Stability

Aliquots of serum samples were stored at -20°C and thawed 5 times, and the human sCD44var (v5) levels determined. There was no significant loss of human sCD44var (v5) immunoreactivity detected by freezing and thawing.

13.5.2. Storage Stability

Aliquots of serum samples were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human sCD44var (v5) level determined after 24 h. There was no significant loss of human sCD44var (v5) immunoreactivity detected during storage under above conditions.

13.6. Comparison of Serum and Plasma

Serum, as well as EDTA, citrate and heparin plasma samples from 22 individuals were obtained at the same time point. All these blood preparations were found suitable for human sCD44var(v5) determinations, although human sCD44var(v5) levels in citrate, EDTA and heparin plasma were slightly lower than serum levels. It is, therefore, highly recommended to assure the uniformity of sample preparations.

13.7. Specificity

The assay recognizes both natural and recombinant forms of the sCD44var(v5) molecule. The interference of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human sCD44var (v5) positive serum. There was no crossreactivity detected, namely not with human sCD44 polypeptides lacking the protein sequence encoded by exon 5.

13.8. Expected Values

A panel of 22 serum samples from randomly selected apparently healthy donors (males and females) was tested for human sCD44var (v5). The detected human sCD44var (v5) levels ranged between 6 and 55 ng/ml with a mean level of 35 ng/ml and a standard deviation of 13 ng/ml.

The levels measured may vary with the sample collection used.

14. Bibliography

1. Arch R., K. Wirth, M. Hofmann, H. Ponta, S. Matzku, P. Herrlich, and M. Zöller. (1992). Participation in normal immune responses of a metastasis-inducing splice variant of CD44. *Science* 257, 682-685.
2. Fujiwara K., T. Yoshino, K. Miyake, N. Ohara, and T. Akagi. (1993). Expression of a lymphocyte adhesion molecule (CD44) in malignant lymphomas: relevance to primary site, histological subtype and clinical stage. *Acta Med Okayama* 47, 215-222.
3. Günthert U., M. Hofmann, W. Rudy, S. Reber, M. Zöller, I. Haußmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell* 65, 13-24.
4. Heider K.H., J. Dämmrich, P. Skroch-Angel, H. Müller-Hermelink, H.P. Vollmers, P. Herrlich, and H. Ponta. (1993). Differential expression of CD44 splice variants in intestinal and diffuse type human gastric carcinomas and normal gastric mucosa. *Cancer Res.* 53, 4197-4203.
5. Heider K.H., M. Hofmann, E. Horst, F. van den Berg, H. Ponta, P. Herrlich, and S.T. Pals. (1993). A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. *J. Cell Biol.* 120, 227-233.
6. Herrlich P., W. Rudy, M. Hofmann, R. Arch, M. Zöller, V. Zawadzki, C. Tölg, A. Hekele, S. Pals, K. H. Heider, J. Sleeman, and H. Ponta. (1993). CD44 and splice variants of CD44 in normal differentiation and tumor progression. In: "Cell adhesion molecules". Eds.: D. M. Livingston et al., Edigraf, Rome - in press.
7. Hofmann M., W. Rudy, M. Zöller, C. Tölg, H. Ponta, P. Herrlich, and U. Günthert. (1991). CD44 splice variants confer metastatic behaviour in rats: Homologous sequences are expressed in human tumor cell lines. *Cancer Res.* 51, 5292-5297.
8. Humbria A., F. Diaz-Gonzalez, M.R. Campanero, A.G. Arroyo, A. Laffon, R. Gonzalez-Amaro, and F. Sanchez-Madrid. (1993). Expression of L-selectin, CD43 and CD44 in synovial fluid neutrophils from inflammatory joint diseases. *Arth. Rheumatism.* (submitted).
9. Joensuu H., R. Ristamäki, P.J. Klemi, and S. Jalkanen. (1993). Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. *Br. J. Cancer* 68, 428-432.
10. Koopman G., K.H. Heider, E. Horst, G.R. Adolf, F. van den Berg, H Ponta, P. Herrlich, and S.T. Pals. (1993). Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. *J. Exp. Med.* 177, 897-904.
11. Kuppner M.C., E. van Meir, T. Gauthier, M.F. Hamou, and N. de Tribolet. (1992) Differential expression of the CD44 molecule in human brain tumours. *Int. J. Cancer* 50, 572-577.
12. Lee Guo M.M., and J.E.K. Hildreth. (1993). HIV-induced loss of CD44 expression in monocytic cell lines. *The Journal of Immunology* 151, 2225-2236.
13. Matsumura Y., and D. Tarin. (1992). Significance of CD44 gene products for cancer diagnosis and disease evaluation. *The Lancet* 340, 1053-1058.

14. Möller P., A. Eichelmann, G. Mechtersheimer, and K. Koretz. (1991). Expression of $\alpha 1$ -Integrins, H-CAM (CD44) and LECAM 1 in primary gastro-intestinal B-cell lymphomas as compared to the adhesion receptor profile of the gut-associated lymphoid system, tonsil and peripheral lymph node. *Int. J. Cancer* 49, 846-855.
15. Omary M.B., I.S. Trowbridge, M. Letarte, M.F. Kagnoff, and C.M. Isacke. (1988). Structural heterogeneity of human Pgp-1 and its relationship with p85. *Immunogenetics* 27, 460-464.
16. Salmi M., K. Grön-Virta, P. Sointu, R. Grenman, H. Kalimo, and S. Jalkanen. (1993). Related expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. *J. Cell Biol.* 122, 431-442.
17. Stamenkovic I., A. Aruffo, M. Amiot, and B. Seed. (1991). The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. *EMBO J.* 10, 343-348.
18. Underhill Ch. (1992). CD44: The hyaluronan receptor. *J. Cell Science* 103, 293-298.

15. Reagent Preparation Summary

15.1. Wash Buffer (1x)

Add **Wash Buffer Concentrate** 20x (50 ml) to 950 ml distilled water.

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

15.2. Assay Buffer (1x)

Add **Assay Buffer Concentrate** 20x (5 ml) to 95 ml distilled water.

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

15.3. HRP-Conjugate

Make a 1:20 predilution of the **HRP-Conjugate** in 190 μ l Assay Buffer (1x). Make a further 1:100 dilution in Assay Buffer (1x):

Number of Strips	Prediluted (1:20) HRP-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

15.4. Human sCD44var (v5) Standard

Reconstitute lyophilized **human sCD44var (v5) standard** with distilled water. (Reconstitution volume is stated on the label of the standard vial.)

16. Test Protocol Summary

1. Predilute serum, plasma and urine samples with Sample Diluent 1:6.
2. Determine the number of microwell strips required.
3. Wash microwell strips twice with Wash Buffer.
4. Standard dilution on the microwell plate: Add 100 µl Sample Diluent, in duplicate, to all standard wells. Pipette 100 µl prepared standard into the first wells and create standard dilutions by transferring 100 µl from well to well. Discard 100 µl from the last wells.
Alternatively external standard dilution in tubes (see 9.4.1.): Pipette 100 µl of these standard dilutions in the microwell strips.
5. Add 100 µl Sample Diluent, in duplicate, to the blank wells.
6. Add 80 µl Sample Diluent to sample wells.
7. Add prediluted 20 µl sample in duplicate, to designated sample wells.
8. Prepare HRP-Conjugate.
9. Add 50 µl HRP-Conjugate to all wells.
10. Cover microwell strips and incubate 3 hours at room temperature (18°C to 25°C).
11. Empty and wash microwell strips 3 times with Wash Buffer.
12. Add 100 µl of TMB Substrate Solution to all wells.
13. Incubate the microwell strips for about 10 minutes at room temperature (18°C to 25°C).
14. Add 100 µl Stop Solution to all wells.
15. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed samples have been diluted 1:30 (1:6 external predilution, 1:5 dilution on the plate: 20 µl sample + 80 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 30).

17. Ordering Information

Product Name	Product Description	Size	Catalog Number
sCD44var (v5) ELISA Kit, human	Human soluble CD44 (variant 5) ELISA Kit	96 Tests	PK-EL-63350-5

***For in vitro research use only.
Not for diagnostic or therapeutic procedures.***

PromoCell GmbH

Sickingenstr. 63/65
69126 Heidelberg
Germany

North America

Phone: 1 – 866 – 251 – 2860 (toll free)
Fax: 1 – 866 – 827 – 9219 (toll free)

Deutschland

Telefon: 0800 – 776 66 23 (gebührenfrei)
Fax: 0800 – 100 83 06 (gebührenfrei)

France

Téléphone: 0800 90 93 32 (ligne verte)
Téléfax: 0800 90 27 36 (ligne verte)

United Kingdom

Phone: 0800 – 96 03 33 (toll free)
Fax: 0800 – 169 85 54 (toll free)

Other Countries

Phone: +49 6221 – 649 34 0
Fax: +49 6221 – 649 34 40

Email: info@promokine.info